^
Association details:
| Biomarker: | DCTN1-ALK fusion |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
UPDATED ENTRECTINIB DATA FROM A PHASE 1/2 TRIAL IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Published date:
08/26/2020
Excerpt:
STARTRK-NG (NCT02650401) is a phase 1/2 trial evaluating the efficacy and safety of entrectinib, a CNS-penetrant TRK/ROS1/ALK tyrosine kinase inhibitor, in pediatric patients with primary brain tumors or extracranial solid tumors. Eight patients had fusion-positive extracranial solid tumors (ORR 8/8; 100%), best responses: 3 CR (DCTN1-ALK, ETV6-NTRK3 [n=2]), 5 PR (EML4-NTRK3, KIF5B-ALK, TFG-ROS1 [n=3]).
